title: S2. Rituximab for ANCA-associated vasculitis: the UK experience.
authors.affiliation: Vasculitis & Lupus Clinic, Addenbrooke's Hospital, Box 118, Cambridge, United Kingdom. dj106@cam.ac.uk
authors.forename: David
authors.initials: D
authors.lastname: Jayne
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008134:Long-Term Care; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D055502:Secondary Prevention; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine